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1.INTRODUCTION
ERCC1 (Excision repair cross-complementation group 1) is a key protein involved in the repair of 
DNA alterations, including those induced by classic chemotherapeutic agents [1]. High activity of 
ERCC1-related pathways has been associated in some reports to reduced efficacy as well as 
increased toxicity of chemotherapeutic drugs, such as platinum salts (cisplatin and oxaliplatin) [2]. 
These correlations, however, have not been consistently confirmed in other datasets, especially 
when ERCC1 protein expression was analysed [3].
In cancer biomarker discovery, the assessment of germline genetic polymorphisms that regulate the 
protein expression and activity (functional polymorphisms) of a candidate gene has been sometimes 
deemed as more robust methodology to appreciate their real prognostic/predictive value.[4,5]
Germline polymorphisms of the ERCC1 gene have also been identified [6].They may influence the 
protein expression and have been investigated as biomarkers in cancer patients treated with 
oxaliplatin.
In the present article we first review ERCC1 structure and function and the evidence of ERCC1 
polymorphisms assessment to predict the toxicity and efficacy of oxaliplatin. Then, we confirm 
results from the literature with our local experience by genotyping for ERCC1 rs3212986 and 
rs11615 loci consecutive patients treated between April 2015 and October 2015 with the widely 
used oxaliplatin-based chemotherapy adjuvant regimen FOLFOX 
(fluorouracil/leucovorin/oxaliplatin) in radically resected colorectal cancer patients [7].
2.ERCC1 STRUCTURE AND PHYSIOLOGICAL FUNCTION
ERCC1 is a 32 KDa protein (~300 aminoacid) that in humans operates in tandem with the nearly 
three-fold heavier protein XPF (xeroderma pigmentosum group F). 
It is a crucial component of an important cellular machinery that presides over the genome integrity, 
the nucleotide excision repair (NER) system (figure 1). NER in human cells is a sophisticated 
process which involves dozens of proteins that assemble in a stepwise fashion. Most important NER 
proteins are: XP (xeroderma pigmentosum) group C (or XPC), RNAP (RNA polymerase), 
Cockayne syndrome group A and group B (CSA and CSB), transcription/DNA repair factor IIH 
(TFIIH), ERCC1, XPF (or ERCC4), XP group G (XPG), DNA polymerase, DNA ligase.
Overall, NER recognizes several types of DNA damages, and repairs them by excising the DNA 
oligonucleotide segments containing the damaged spot (usually a 25-30 bp segment).[8] 
ERCC1 lacks of intrinsic nuclease activity, however it is indispensable for the cleavage of altered 
DNA sequences carried out by the eterodimer ERCC1/XPF endonuclease.
ERCC1 is constituted by a central domain, which interacts with both proteins and DNA (in 
particular single strand DNA, ssDNA), and by a HhH (helix–hairpin–helix) domain, which secures 
the interaction with both the XPF subunit (the one that contains the nuclease catalytic region) and 
double strand DNA (dsDNA) segments. The DNA cleavage by ERCC1/XPF is performed in 5’ at 
junctions between ssDNA and dsDNA structures such as those seen in the DNA bubbles created 
during NER (figure 2). [9]
ERCC1 and XPF are usually found in the nucleus as a dimer and are reciprocally essential in terms 
molecular stability, so that ERCC1 defective cells are also XPF-deficient and vice versa.[10,11] 
Four isoforms of ERCC1 generated by alternative splicing have been identified, namely isoform 
201, 202, 203 and 204, however only isoform 202 seems to have DNA repairing potential [12].
Steps encountered in NER are now well-defined and are in common with those observed in 
prokaryotes (e.g. E. coli) [13]. First, proteins sensing the DNA damage are activated. Two types of 
complexes can be involved in this phase: the XPC-based complexes or the RNAP/CSA/CSB-based 
complexes. The latter are involved in the repair of lesions in the transcribed strand of active genes 
(Transcription-coupled repair, TCR). It has been demonstrated that lesions that occur in the 
transcribed strand of active genes are repaired more rapidly than those occurring in the opposite 
strand of the same genes [14]. XPC-based complexes are involved in all the other DNA lesions 
(Global genomic repair, GGR). These NER multiproteins that at first recognize the genomic insult 
are responsible for an initial melting of the DNA around the lesion and favour the access of a 
second-step multiprotein complex: the TFIIH-based complex.
TFIIH-based complex creates a 20-30 bp ‘bubble’ around the damaged area by separating the DNA 
double strand. 
A third step is carried out by the ERCC1/XPF(ERCC4) complex, which is responsible for the 
incision in 5’ of the altered strand, and by XPG that completes the incision in 3’. 
A DNA polymerase complex is then activated that replaces the damaged 20-30 bp segment with the 
normal nucleotide sequence on the base of the intact opposite ssDNA template. Finally a ligase 
complex seals the newly generated repaired segment (figure 1).
Figure 1. Schematic representation of the activity of the NER (nucleotide excision repair) system.
Figure 2 Structure and function of the ERCC1/XPF complex
Although it is recongnized that ERCC1 has a principal role in the NER machinery, other important 
functions of this protein have been identified.
The dimer ERCC1–XPF has functions in the direct repair of interstrand crosslinks and intervenes in 
some aspects of the homologous recombination and of the non-homologous end-joining (NHEJ) for 
the repair of DSB (double strand breaks). Finally, it also takes part in the Base Excision Repair 
(BER) and in the Telomere Length regulation. [15] 
Preclinical and clinical models of defective ERCC1 function have helped clarify the physiological 
role of this protein and its possible use as pharmacological target. 
Up to now one patient with the Cockayne syndrome, a syndrome characterized by microcephaly 
and delayed development (patient CS20LO), and one patient with a cerebro-oculo-facio-skeletal 
syndrome (patient 165TOR), have been found with inherited mutations of ERCC1 gene, suggesting 
that genome integrity guaranteed by this pathway is essential in human development.[16,17] 
Several mouse models of mutated ERCC1 have also been created to confirm the differential role of 
ERCC1 domains (in particular of the central domain and the HhH domain) [18]. Many of these 
mutations have been proven incompatible with life and with early development. On the contrary, 
deletion of the first 91 amino acids of protein sequence does not affect ERCC1 function.[19,20]
 
3.ERCC1 AND CHEMOTHERAPY
Classic chemotherapeutic drugs, such as platinum salts, are known to execute their tumoricidal 
action by directly injuring DNA integrity, an effect that invariably induces cell apoptosis. DNA 
repair systems, such those driven by ERCC1, counteract the DNA-damaging effect of 
chemotherapy and therefore may be associated with drug resistance.
In 1990s first reports on the reduced efficacy of cisplatin in patients bearing tumors with high 
expression of ERCC1 were published.[21-23] 
In a seminal work by Dabholkar et al [24], 26 patients with ovarian cancer treated with cisplatin 
were analyzed for the expression of ERCC1 mRNA in the fresh tumor tissue. 
They found a nearly 3-fold higher expression of ERCC1 mRNA in non responding patients as 
compared to platinum-sensitive patients (p 0.015).
After Dabholkar’s report, a number of other studies have investigated the potential effect of ERCC1 
expression on cisplatin efficacy with contradictory results. 
Metzger et al evaluated the combinatorial test of ERCC1 and TS (Thymidilate Synthase) mRNA 
expression in 36 gastric cancer patients undergoing neo-adjuvant cisplatin/fluororuracil 
chemotherapy[25]. They found that response rate was 85% for patients with both ERCC1 and TS 
mRNA below the median as compared to 20% for patients with high ERCC1 and TS (p 0.003)
Olaussen et al used immunohistochemistry to assess ERCC1 protein expression in a large number 
of patients with lung cancer, n=761, undergoing adjuvant chemotherapy with cisplatin within the 
International Adjuvant Lung Cancer Trial (IALT). ERCC1 was positive in 44% of patients. The 
benefit of adiuvant cisplatin, as compared to the no-chemotherapy arm, was observed only for 
patients with ERCC1 negative tumors (median survival 56 vs 42 months, respectively, P=0.002)
Patients with ERCC1 positive tumors derived no benefit from adjuvant cisplatin-based 
chemotherapy (median survival 50 vs 55 months, respectively, P=0.40) [26] 
More recently, however, a clear discrepancy was found in the frequency of protein expression in 
lung tumor tissue and doubts were raised on the technical reliability of ERCC1 
immunohistochemical assessment. In fact, although using the same antibody, the mouse anti-human 
ERCC1 8F1, in a validation set of about 500 samples from other two randomized adjuvant trials 
(JBR.10 and CALGB 9633), the ERCC1-positivity rate was found to be 77%, sensibly higher than 
previously reported [27]. The same authors eventually demonstrated a significant sensitivity 
difference between the 8F1 batch originally used in 2006 and the new 8F1 used in 2011, with the 
predictive and prognostic role of ERCC1 no longer confirmed. Other 15 anti-ERCC1 were also 
tested, with none of them proven of prognostic/predictive value. Moreover, none of them was able 
to recognize the ERCC1 isoform with effective DNA-repairing activity (isoform 202). The authors 
concluded that further optimization of ERCC1 immunhistochemical assessement was needed to 
validate this protein as a biomarker.
Oxaliplatin is a sencond-generation platinum salt, chemically modified to reduce renal toxicity. It is 
widely used for the treatment of tumors of the gastrointestinal tract and is a key component of 
FOLFOX, the most utilized adjuvant regimen in treating colorectal cancer patients [28].
Mechanism of action of oxaliplatin is similar to that of cisplatin and ERCC1 has also been assessed 
as biomarker in oxaliplatin-treated patients.
Shirota et al, analysed ERCC1 mRNA expression, togheter with TS mRNA expression, in 50 
colorectal cancer patients candidate for a second-line FOLFOX after progression to 
fluorouracil/irinotecan. Patients with high ERCC1 mRNA (number of patients: 10 out of 50), based 
on an investigator-defined cutoff, had shorter survival as compared to patients with low ERCC1 
mRNA levels, median survival 10 vs 2 months, p < 0.001. However, ERCC1 did not predict for 
radiologic response [29].
ERCC1 immunhistochemical expression was evaluated in 1,197 colorectal cancer patients enrolled 
in the FOCUS trial, that compared the sequential use of active chemotherapeutic drugs 
(fluorouracil, irinotecan and oxaliplatin) with their concomitant use in polychemotherapy regimens 
(FOLFIRI or FOLFOX). ERCC1 protein expression had no predictive value for the efficacy of 
combination chemotherapy vs sequential monotherpy [30].
Given that the contradictory data on the role of ERCC1 as cancer biomarker is due, at least in part, 
to the technical difficulties in assessing ERCC1 mRNA or protein in a reproducible and robust 
fashion, it has been hypothesized that germline functional ERCC1 polymorphisms that ultimately 
influence the protein expression might be a more ‘stable’ methodology to assess ERCC1 influence 
as putative biomarker for patient outcome. ERCC1 gene has known functional polymorphisms that 
have been tested as predictor of oxaliplatin efficacy and toxicity.
4.ERCC1 POLYMORPHISMS AND OXALIPLATIN
Currently, no known non-synonymous SNPs in the coding region of the ERCC1 gene with potential 
clinical utility have been identified. There are two valuable synonymous germline ERCC1 gene 
polymorphisms not altering the final product aminoacid sequence/structure that have been actively 
studied for their predictivity in platinum-treated cancer patients: rs3212986 (also named ERCC1 
C8092A or *197G>T) and rs11615 (also named ERCC1 T19007C or ERCC1 C118T or ERCC1 
Asn118Asn). The former lies in the 3’ untranslated region (3’-UTR), the latter is a synonymous 
point mutation in exon 4. Both of them are supposed to influence the stability and the nuclear levels 
of ERCC1 mRNA and hence the ERCC1 protein expression.[31-34] In particular 118T allele of 
rs11615, even if not determining a change in the amino acid (Asn 118 Asn), was hypothesized to 
reduce the translation efficiency of ERCC1 mRNA with consequent reduced ERCC1 protein 
expression [35]. However, some authors found no change in mRNA and protein levels with either 
genetic variant [36], and suggested that the possible clinical impact of these SNPs would reside in a 
genetic linkage with still unknown haplotypes of proximal genes conferring resistance/sensitivity to 
chemotherapeutic drugs.
Other 3 SNPs have been indentified lying in intron 3, 4, and 5: IVS3 +74C>G (rs3212948), IVS4 
+86T>C (rs3212955) and IV5 +33C>A (rs3212961), respectively, but these are less commonly 
investigated because of their rarity.  
A systematic pubmed search was performed using the following search terms: ERCC1 
polymorphisms AND oxaliplatin. As for October 2016, 52 article in English were retrieved, the 
following sections will review published findings on the impact of ERCC1 polymorphisms on 
oxaliplatin efficacy and toxicity. Henceforth wild type ERCC1 alleles will be abbreviated as WT 
and the minor/mutated alleles as MUT.
ERCC1 polymorphisms as predictive markers for oxaliplatin-treated cancer patients have been 
evaluated in gastroesophageal cancer, colorectal cancer and nasopharyngeal cancer.
4.1.ERCC1 SNPs and oxaliplatin in gastroesophageal cancer
A number of reports have been published on the usefulness of ERCC1 polymorphisms in 
gastroesophageal cancer patients, in different disease settings: adjuvant, neo-adjunvant and 
metastatic setting. 
Among the others, a study by Huang et al evaluated the role of ERCC1 rs11615 in 89 patients 
treated, after radical resection, with at least four cycles of oxaliplatin-based adjuvant chemotherapy. 
No significant difference was detected in terms of either relapse free survival or overall survival. In 
particular WT/WT patients (50% of patients) had a median survival of 29 months as compared to  
26 months for patients with the WT/MUT genotype (43% of patients) or MUT/MUT genotype (7% 
of patients), P = 0.214. In the same study authors evaluated the effect of ERCC1 mRNA expression 
level in tumor tissue, which was available for 62 patients. A great inter-patient variability was found 
and no significant difference in ERCC1 mRNA level was observed across different rs11615 
genotypes. ERCC1 mRNA, however, significantly correlated with survival, with a median survival 
of 29.6 months for patients with low ERCC1 mRNA as compared to 18.7 months for patients with 
high ERCC1 mRNA. [37]
Li et al [38] evaluated ERCC1 rs3212986 SNP (Single Nucleotide Polymorphism), together with 
other 23 SNPs involved in chemotherapeutic drug metabolism, in 103 gastric cancer patients 
undergoing neoadjuvant oxaliplatin+fluropirimidine-based chemotherapy (either FOLFOX, 
XELOX or SOX regimen). They found no clear association between ERCC1 rs3212986 SNP and 
either short-term activity (tumor regression grade) or long-term activity (overall survival) of the 
chemotherapy. Among all analyzed SNP, rs717620 SNP of ABCC2 gene (a membrane transporter 
responsible for chemotherapy drug cell efflux) was significantly associated with both overall 
survival and tumor regression (i.e. TGR 1a or 1b).
The authors made available the database of  enrolled patients including data on ERCC1 rs3212986 
SNP and respective TRG which was tested on 101 patients out of 103. Percentage of TRG 1 
response was 19.5%, 12.5% and 25%, for ERCC1 rs3212986 WT/WT, WT/MUT and MUT/MUT 
genotype, respectively, chi square p-value 0.4902.  
Goekkurt et al analyzed germline polymorphisms in 11 key genes (namely TS, MTHFR, MTR, 
OPRT, XPD, ERCC1, XRCC1, XPA, GSTP1, GSTT1, and GSTM1) in patients with metastatic 
gastroesophageal adenocarcinoma enrolled in a phase III AIO (Arbeitsgemeinschaft Internistische 
Onkologie) study comparing fluorouracil/leucovorin/cisplatin (FLP) to 
fluorouracil/leucovorin/oxaliplatin (FLO). [39]
In the patients eligible for the pharmacogenomic study (total number 134 pateints, FLO = 71 
patients, FLP = 63 patients), they found polymorphisms of TS, GSTT1, OPRT and XRCC1 genes to 
be significantly associated with overall survival, while TS,  MTR , GSTP1 and ERCC1 were 
associated with haematological toxicity and with neuropathy.
For ERCC1, rs11615 and rs3212986 SNPs were analysed. They were found to be in linkage 
disequilibrium (P<.0001) and frequency of the commonest haplotype (ERCC1 118T/8092C) was 
55%. There was no significant association of the two ERCC1 SNPs with either overall survival or 
progression free survival. However, the response rate for ERCC1 rs3212986 WT/WT, WT/MUT 
and MUT/MUT genotypes were 44%, 27% and 71%, and the higher response associated with the 
rare MUT/MUT genotype (found in only 7 patients) was statistically significant, p 0.029.
ERCC1 rs11615 MUT/MUT genotype was associated with a non-significant superior grade 3-4 
incidence of anemia, leukopenia and neutropenia as compared to WT/WT genotype (13% vs 5%, 
13% vs 5%, 26% vs 10%, respectively). ERCC1 rs3212986 MUT/MUT genotype was also 
associated with a non-significant superior incidence of grade 3-4 anemia as compared to WT/WT 
(14% vs 9%, respectively). When considered as haplotype, the effect of ERCC1 SNPs on Grade 3-4 
neutropenia became significant (P .042).
4.2.ERCC1 SNPs and oxaliplatin in colorectal cancer
The largest study with a pre-planned prospectively performed analysis of ERCC1 gene variants in 
colorectal cancer patients was the TOSCA trial [40].
The TOSCA trial randomized patients in the adjuvant setting to either six or three months of 
fluoropyrimidine/oxaliplatin chemotherapy (either FOLFOX-4 or CAPOX).
There were 517 patients assessable for the pharmacogenetic substudy (256 and 261 in the six and 
three months arm, respectively). The genes investigated were involved in drug 
pharmacokinetics/pharmacodynamics and had demonstrated promising results in small retrospective 
reports (17 polymorphisms in 11 genes, including ERCC1, GST, MTHFR and ABCC). So far, only 
the impact of genotypes on toxicity has been reported.
Overall the study could not find any significant association between pharmacogenetic markers and 
toxicity. There was no substantial difference in grade 3-4 neutropenia for carriers of ERCC1 
rs11615 MUT/MUT (17% of patients)  vs WT/WT (38% of patients), odds ratio 1.17, p 0.584. 
Similar results were observed for incidence of peripheral neuropathy (odds ratio 0.75, p 0.356). 
Details in the incidence of other haematological toxicities, such as anemia, were not reported. Some 
drawbacks could be observed in the study. Half of the TOSCA patients (261 out of 517 patients) 
received, as per protocol, only three months of chemotherapy, which is not the present standard of 
care. Moreover, Grade 2 hematologic toxicities were neglected in the TOSCA pharmacogenetic 
analysis, though they were also clinically important since, according to the protocol, grade 2 
toxicities imposed treatment delay, and if persistent, dose reduction.
For other four randomized trials, that included the use of oxaliplatin in colorectal cancer, the role of 
ERCC1 polymorphisms has been retrospectively investigated. 
The FFCD 2000-05 was a phase III randomized trial in the pre-biologics era, comparing two 
different sequential strategies in the metastatic setting [41]. Arm A: first-line FOLFOX followed at 
progression by second-line FOLFIRI vs Arm B: first-line 5FU-only regimen  followed at 
progression by second-line FOLFOX followed at progression by third-line FOLFIRI.
ERCC1 rs11615 polymorphism was tested in 174 patients receiving FOLFOX as first line (arm A) 
and in 130 patients receiving FOLFOX as second line (arm B). Other three polymorphisms of 
ERCC1 (rs3212948, rs3212955 and rs3212961) and polymorphisms of other genes of interest 
(DPD, TS, MTHFR, ERCC2, GSTP1, GSTM1, GSTT1, and UGT1A1) were also tested.
Overall, grade 3-4 hematologic toxicity was seen in 71 out of 183 patients (39%) carrying the 
ERCC1 rs11615 MUT allele (MUT/MUT or WT/MUT genotypes) and in 37 out of 121 patients 
(30%) with rs11615 WT/WT genotype (chi-square p-value 0.14). Differences in toxicity were 
similarly non significant also for the other ERCC1 SNPs. Also gastrointestinal toxicity and 
peripheral neuropathy were not associated with ERCC1 SNPs. However, the K751Q polymorphism 
of ERCC2 gene (another gene involved in NER) was significantly associated with grade 3-4 
hematologic toxicity, with a significantly shorter time to hematologic toxicity occurrence for 
ERCC2 K751Q C/C genotype as compared to A/A and A/C genotypes. Response rate to first-line 
FOLFOX was fairly high (60-70%) with no difference across ERCC1 genotypes. ERCC1 rs11615 
MUT allele was associated to 27% response rate to second-line FOLFOX as compared to 19% for 
the ERCC1 rs11615 WT/WT genotype (chi-square p value 0.35). GSTT1 and MTHFR genotypes 
were significantly associated with response to FOLFOX. 
As for survival, in the FFCD 2000-05 trial it was not possible to demonstrate an overall survival 
benefit with the upfront use of FOLFOX as compared to a 5FU-only first-line regimen, median 
survival  16.2 vs 16.4 months [42]. However, ERCC1 rs11615  was of border-line statistical 
significance as predictive marker of upfront use of FOLFOX. First-line use of FOLFOX was 
associated with a favourable Hazard Ratio of 0.77 for carriers of the ERCC1 rs11615 MUT/MUT 
genotype, p 0.07 at the multivariate analysis.
The N9741 trial randomized colorectal cancer patients to three first-line options: FOLFOX, IROX 
or IFL. In a post-hoc analysis of 520 patients, germline DNA was tested for the genotype of 15 
candidate genes.  For the FOLFOX arm, 290 patients were assessed for ERCC1 rs11615 SNP. The 
ERCC1 rs11615 WT/WT genotype was significantly associated with lower grade 4  neutropenia as 
compared to the other genotypes, 13% vs 25%, respectively, p value 0.05. Febrile neutropenia was 
also less frequent in ERCC1 rs11615 WT/WT subjects (0% v 10%, p 0.02).
These results were not reproduced for the 107 patients treated in the IROX arm.
ERCC1 genotype was not associated with tumor response (p 0.86) and overall survival (p 0.62) in 
both FOLFOX-treated patients and in IROX-treated patients (p 0.07 and p 0.55, respectively). 
Authors found other polymorphisms to be predictive of toxicity or outcome. In particular mutations 
in the GTSM1 gene were predictive of neutropenia and mutations in GSTP1 were predictive of 
neurotoxicity in patients treated with FOLFOX. [43]
A third randomized trial for which a pharmacogentic analysis was performed is the NORDIC-VII 
trial. Analysis of 17 germline SNPs in 10 key genes involved in drug biotransformation, transport 
and DNA repair was carried out in 519 enrolled patients. The NORDIC-VII trial tested the addition 
of cetuximab to a standard first-line oxaliplatin/fluorouracil-based chemotherapy (the FLOX 
regimen) in metastatic colorectal cancer patients mainly from north Europe regions (Norway and 
Sweden). ERCC1 SNPs were associated with neither survival nor toxicity. However, ERCC2 
rs23840 minor allele was associated with favourable progression free survival.[44]
More recently, the pharmacogenomic analysis of patients enrolled in the COIN and COIN-B studies 
(that included treatment with fluoropyrimidine, oxaliplatin and cetuximab) was presented as a 
poster at the 2013 ASCO annual meeting.[45,46] Genes of drug metabolism, EGFR pathway or 
DNA repair (overall 259 allelic variants in 143 genes) were investigated in 2183 patients. In 
particular, data on ERCC1 genetic variants were not reported. However, PIK3R2, EXO1 and 
XRCC1 were polymorphic genes with significant associations with 12-week response, and DPYD 
was a gene with significant association with toxicity [47].
4.3.Meta-analyses in patients with cancer of the gastrointestinal tract 
Several authors have tried to meta-analyze available data of the effect of ERCC1 polymorphisms on 
the outcome of oxaliplatin-treated colorectal and gastric cancer patients [48].
Overall, no clear association with clinical outcome (radiologic response rate and survival) has been 
shown. 
A trend to worse outcome associated with the mutant/minor variant (the T allele) of ERCC1 
rs11615 has been observed in some studies, especially on Asian population [49]. This evidence is 
somehow contradictory of the biologic rationale, as it is supposed that the mutant allele is 
associated with less expression of ERCC1, less DNA repair efficiency and hence superior 
oxaliplatin activity. The possible explanation could be a linkage disequilibrium in some ethnic 
groups of ERCC1 with other key genes remaining still unknown. In studies with Caucasian 
populations the opposite trend has been observed, with better outcome associated with the T allele 
of ERCC1 rs11615 [50].
The largest meta-analysis was conducted by Qian et al, who selected 22 studies for a total of 2,846 
colorectal cancer patients. The mutant ERCC1 rs11615 T allele (homozygous or heterozygous) was 
associated with a significantly favourable progression free and overall survival in the Caucasian 
population (Hazard Ratios 0.58 and 0.38, respectively) and significantly worse survival in the Asian 
population (Hazard Ratios 2.49 and 2.63, respectively). No difference in terms of radiologic 
response was observed [51].
4.4.ERCC1 SNPs and oxaliplatin in Nasopharingeal cancer
A single report has been published on the effect of ERCC1 SNPs in oxaliplatin-treated 
nasopharyngeal cancer patients [52]. 
A phase II study enrolling 42 patients with recurrent nasopharyngeal cancer, mainly metastatic 
disease (60% of patients), was conducted by Ma et al. ERCC1 rs11615 was genotyped in 29 
patients. Due to the small sample size, no significant difference in terms of survival was observed:  
median overall and progression free survival for rs11615 CC vs CT+TT, 19.6 vs 22 months and 10 
vs 9.6 months, respectively, p values 0.76 and 0.82.
5. A UNIVERSITY HOSPITAL MONOCENTRIC EXPERIENCE
5.1.Patients and Methods
Between April 2015 and November 2015, all consecutive patients radically resected in our hospital 
(the Tor Vergata University Hospital of Rome, Italy) for a node-positive colon cancer and deemed 
eligible, as per standard practice, for adjuvant chemotherapy with the FOLFOX regimen were 
included in the present pharmacogenomic study. Enrolled patients were systematically tested for 
eight polymorphisms in seven key genes proved to influence outcome and toxicity of 
fluoropyrimidine and oxaliplatin in previous reports.
The seven selected genes and respective polymorphisms were: GSTP1 (rs1695), XRCC1 (rs25487), 
ERCC1 (rs3212986 and rs11615), UGT1A1 (rs8175347), CYP3A5 (rs776746), MTHFR 
(rs1801131) and DPYD (rs3918290).
An EDTA peripheral blood sample (3 mL) was used to extract white blood cell DNA and assess for 
germline polymorphisms. Genetic variants were determined by a first step target sequence 
amplification using standard PCR and a second step of pyrosenquencing according to standard 
procedure (see manufacturer instructions at www.diatechpharmacogenetics.com). In table 1 are 
summarized the allelic variants and the functional significance of minor alleles of analyzed 
polymorphisms.
Gene polymorphism wild type
minor 
variant
Position in the gene and 
chromosome Significance
GSTP1 rs1695 A G exon 5, position 562 substitution of Ile with a Val at position 105 of the amino acid sequence of the protein. Diminishes GSTP1 enzyme activity
XRCC1 rs25487 A G exon 10, position 1316
substitution of Gln with an Arg at position 399 of the amino acid 
sequence of the protein.Defects in the detection of the DNA damage 
by XRCC1 and hence the activation of the BER pathway. 
ERCC1 rs3212986 C A UTR-3, position 1165 reduced mRNA stability
ERCC1  rs11615 T C exon 4, position 500 synonimous mutation at position 118 of the protein. Reduced mRNA translation 
UGT1A1 rs8175347 [TA]6 [TA]7 TATA box of the promoter, position reduced expression 
CYP3A5 rs776746 A G intron 3, position 12083 Splice variant with premature termination codon and non functional protein
MTHFR rs1801131 A C exon 8, position 1515
substitution of glu to ala at position 429 of the protein. Reduced 
enzyme activity with reduced conversion of conversion of MTHF to 
BH4 (tetrahydrobiopterin)
DPYD rs3918290 G A Intron 14, position 476002 exon-skipping mutation. Altered non-functional protein 
Table 1 polymorphisms assessed in the Tor Vergata monocentric study
Patients were managed as per standard practice, in particular routine blood tests, including blood 
cell count were performed at each of the 12 planned cycles. Chemotherapy-related toxicities were 
recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 
(https://www.nih.gov/).
Study endpoint was to correlate genotypes with early changes of haematological variables, in 
particular with early decline in white blood cell count, neutrophil count, lymphocyte count, 
haemoglobin concentration and platelet count. 
Given the small sample size included so far, no formal analysis of CTCAE toxicity and patient 
survival has been conducted. The effect of genotypes on haematological variables changes in the 
present pilot study has been considered as a potential useful marker of subsequent more profound 
myelotoxicity over the course of the adjuvant treatment.
Univariate and Multivariate multiple regression analyses, setting as dependent variable the 
percentage change of haematological variables after two cycles of chemotherapy and as 
independent variable the analyzed genotypes, were performed to screen for potentially valuable 
biomarkers of toxicity.
The value of 0, 1 or 2 for each genotype was assigned depending on the number of minor alleles 
found at the analysis. Polimorphisms found to be significantly associated with haematological 
variable changes at univariate analysis were selected to be run at the multivariate analysis.
Mann-Whitney test were used to confirm statistically significant differences found at the regression 
analysis. 
The present research has been carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for experiments involving humans. Informed consent 
from participating patients was obtained before study entry. The privacy rights of human subjects 
have been observed.
5.2.Results
Sixteen patients were enrolled in the study. In the table 2 are summarized patients’ characteristics.
At univariate analysis ERCC1 polymorphisms were associated with the decline of all type of 
analyzed blood cells but platelets (table 3). UGT1A1 and GSTP1 were also associated with 
Leucocyte decline at both univariate and multivariate regression analysis, however at the 
multivariate analysis ERCC1 rs11615 was the polymorphism with the highest statistical 
significance (p values 0.002 vs 0.02 vs 0.03, respectively). The DPYD polymorphism was also 
associated with lymphocyte count changes together with ERCC1 rs3212986. However, also in this 
case, the ERCC1 polymorphism displayed the highest statistical significance (p value 0.002 vs 
0.004, respectively).
According to the subsequent Mann-Whitney analysis, ERCC1 rs3212986 was significantly 
associated with percentage change in haemoglobin concentration after 2 cycles of FOLFOX.
Patients heterozygous for rs3212986 (WT/MUT) experienced a median reduction of Hb 
concentration of 4%, which was significantly different from the Hb change of patients WT 
homozygous who experienced an increase of Hb concentration by 7%, p 0.0011 (figure 3). No other 
significant associations were detected with the Mann-Whitney tests. 
Out of 16 enrolled patients, three patients experienced significant treatment delay, dose reduction or 
even early discontinuation because of grade 3-4 anemia (HB < 8gr/dL). All those three patients 
were ERCC1 rs3212986 eterozygous. Because of the immature follow-up and the limited sample 
size, no analysis on outcome measures (disease free and overall survival) or comprehensive toxicity 
data have been performed.
Number of patiens = 16
Characteristic Value
sex, male:female 12:6
Age 61years (range 52-75)
hematological variables Baseline % change after 2 cycles
Hb 12.3 g/dL +3%
WBC 5.7 -13%
Neutrophil 3.5 -29%
Lymphocyte 1.8 +5%
Platelets 261 -13%
Genotypes wt/wt wt/mut mut/mut
GSTP1 A313G 4 10 2
XRCC1 G28152A 10 6 0
ERCC1 C8092A rs3212986 10 6 0
ERCC1 C118T rs11615 6 8 2
UGT1A1*28 2 12 2
CYP3A5*3 12 4 0
MTHFR A1298C rs1801131 4 8 4
DPYD IVS14+1G>A rs3918290 12 4 0
Table 2 Tor Vergata patients’ characteristics, Hb: haemoglobin; WBC: white blood cells; GSTP1: 
glutathione S-transferase P1; XRCC: X-ray repair cross complementing 1; ERCC1: Excision repair 
cross-complementation group 1; UGT1A1 UDP glucuronosyl transferase family 1 member A1; 
CYP3A5: cytochrome P450 family 3 subfamily A member 5; MTHFR: methylene-tetra-hydro-
folate reductase; DPYD dihydro-pyrimidine dehydrogenase
UNIVARIATE MULTIVARIATE
Dependent 
variable
Independent 
variables Coefficient Std. Error rpartial t P Coefficient Std. Error rpartial t P
CYP3A5 -0,34 0,1805 -0,4497 -1,884 0,0806
DPYD -0,1533 0,1979 -0,2028 -0,775 0,4513
ERCC1_C8092A 0,02933 0,1806 0,04337 0,162 0,8733
ERCC1_T19007C -0,2657 0,1116 -0,5368 -2,381 0,032 -0,2811 0,07272 -0,7447 -3,865 0,0022
GSTP1 0,2835 0,1248 0,519 2,272 0,0394 0,2148 0,08828 0,5749 2,434 0,0315
MTHFR 0,025 0,1236 0,05399 0,202 0,8426
UGT1A1 0,375 0,1435 0,5727 2,614 0,0204 0,2676 0,1055 0,5907 2,536 0,0261
WBC 1-month-
change
XRCC1 0,328 0,1581 0,485 2,075 0,0569
CYP3A5 -0,1283 0,1659 -0,2025 -0,774 0,4521
DPYD 0,3917 0,1332 0,6179 2,94 0,0107 0,3382 0,09818 0,6908 3,445 0,0044
ERCC1_C8092A 0,366 0,1157 0,6456 3,163 0,0069 0,3209 0,08781 0,7119 3,654 0,0029
ERCC1_T19007C 0,085 0,1086 0,2048 0,783 0,4467
GSTP1 0,1291 0,1174 0,282 1,1 0,2899
MTHFR 0,055 0,1027 0,1417 0,536 0,6007
UGT1A1 0,015 0,1467 0,02732 0,102 0,92
Lymphocyte 1-
month-change
XRCC1 -0,05533 0,1508 -0,0976 -0,367 0,7192
CYP3A5 -0,3867 0,2167 -0,4305 -1,785 0,096
DPYD -0,26 0,2298 -0,2895 -1,132 0,2768
ERCC1_C8092A 0,09067 0,2133 0,1129 0,425 0,6773
ERCC1_T19007C -0,4343 0,1059 -0,7386 -4,1 0,0011
GSTP1 0,1843 0,1662 0,2842 1,109 0,2861
MTHFR 0,08 0,1454 0,1455 0,55 0,5909
UGT1A1 0,345 0,1863 0,4435 1,852 0,0853
Neutrophil 1-
month-change
XRCC1 0,2773 0,2015 0,3452 1,376 0,1903
CYP3A5 0,07833 0,04874 0,3947 1,607 0,1303
DPYD -0,075 0,04911 -0,3779 -1,527 0,149
ERCC1_C8092A -0,13 0,03231 -0,7323 -4,024 0,0013
ERCC1_T19007C 0,03929 0,0331 0,3024 1,187 0,255
GSTP1 0,03174 0,03736 0,2214 0,849 0,4099
MTHFR 0,015 0,03223 0,1234 0,465 0,6488
UGT1A1 0,075 0,04133 0,4363 1,814 0,0911
Hb 1-month-
change
XRCC1 0,08333 0,04189 0,4694 1,989 0,0666
CYP3A5 -0,4117 0,2955 -0,349 -1,393 0,1853
DPYD -0,3183 0,3036 -0,2698 -1,049 0,3121
ERCC1_C8092A 0,2953 0,2707 0,2799 1,091 0,2937
ERCC1_T19007C -0,2821 0,1921 -0,3653 -1,468 0,1641
GSTP1 0,3335 0,2096 0,3914 1,591 0,1339
MTHFR -0,145 0,1891 -0,2007 -0,767 0,456
UGT1A1 0,1 0,2717 0,09788 0,368 0,7184
PLT 1-month-
change
XRCC1 0,1567 0,2789 0,1485 0,562 0,5831
TABLE 3 Univariate and Multivariate regression analysis. Hb: haemoglobin; WBC: white blood 
cells; PLT: platelets; GSTP1: glutathione S-transferase P1; XRCC: X-ray repair cross 
complementing 1; ERCC1: Excision repair cross-complementation group 1; UGT1A1 UDP 
glucuronosyl transferase family 1 member A1; CYP3A5: cytochrome P450 family 3 subfamily A 
member 5; MTHFR: methylene-tetra-hydro-folate reductase; DPYD dihydro-pyrimidine 
dehydrogenase
-0,1
0,0
0,1
0,2
Hb change
ERCC1_rs3212986="wt/mut"
Hb change
ERCC1_rs3212986="wt/wt"
p 0.0011
-4%
+7%
Figure 3 Mann-Whitney test comparing the percentage change of haemoglobin concentration after 
2 cycles of chemotherapy by rs3212986 genotype. Hb: haemoglobin; ERCC1: Excision repair 
cross-complementation group 1; wt: wild type; mut: minor/mutant allele.
6.CONCLUSIONS
In the present article we reviewed the evidence on the role of ERCC1 polymorphisms in the 
prediction of outcome and toxicity of patients treated with oxaliplatin. Moreover, in the absence of 
a virtual perfect trial (what we call a ‘sliding doors’ trial) we assessed the clinical utility of 
systematically genotyping key genes in our local practice.
In clinical practice the primacy of two medical goals has to be acknowledged, namely overall 
survival and quality of life. Physicians, with their treatment and management, must aim, above  all, 
at helping patients to live as long and as well as possible. The tools with the highest methodological 
quality to find the best way to manage patients are randomized clinical trials on patients with 
homogeneous characteristics (i.e. same distribution of gender, age and other important 
characteristics).  
But, how do we define homogeneity thoroughly in a patient cohort? The ideal methodological 
setting would be to have two ‘identical’ groups of subjects to whom two (or more) distinct types of 
protocol could be administered, so that the net management effect is ‘isolated’. The co-primary 
endpoints must be overall survival and quality of life and the only variable influencing the outcome 
should be the administered therapy/protocol itself.
In this regard, the perfect trial is a ‘sliding doors’ trial, to quote the popular 1998 Gwyneth Paltrow 
movie, where the  same character lives two parallel lives, thanks to a sort of magic. In a ‘sliding 
doors’ trial every single patient would be made to live two parallel disease histories, with two 
alternative management strategies, to assess which one has the best outcome for ‘that  individual  
patient’.
In the absence of magic, a high degree of patient cohort homogeneity is the best approximation to a 
perfect sliding doors trial.
In this context, how does the ‘monocentric’ nature of a study contribute to cohort homogeneity?. 
Although a major flaw of monocentric studies is the absence of external validation, they guarantee  
‘geographical’ homogeneity, that is to say more homogeneous genetic backgrounds, routine 
practices and environmental factors.
Therefore, monocentric studies that are carried out in order to confirm locally, in a limited 
geographical area, the results of large international trials can be regarded as important tools to 
measure inter-‘clinical environment’  heterogeneity, including differences in clinical practices, in 
patient characteristics or the availability of medical facilities. A similar utility of monocentric 
studies is that they enable us to validate in a given clinical ‘habitat’ contradictory results that have 
been published on a specific topic.
Hypothetically an ‘x’ correction factor measuring the distance between the perfect sliding doors 
trial and the degree of patient homogeneity of a published clinical trial, and an ‘y’ correction factor 
measuring the distance between the patient characteristics of a published trial and the characteristics 
of an individual patient that is being treated in a given local area, could be introduced into the 
decision making algorithms (for example, in online software for adjuvant chemotherapy) (figure 4).
The present article is an example of the utility of confirming in a single clinical center contradictory 
results previously published on important clinical issues.
Published data on ERCC1 polymorphisms and efficacy of oxaliplatin have been inconsistent. 
Overall, ERCC1 SNPs cannot be considered as standard marker of survival or radiologic response 
in oxaliplatin-treated patients. The functional effect of ERCC1 SNPs on the protein expression has 
also been questioned, even though in vitro experiments cannot always reproduce the complex 
mechanisms regulating the transcription and translation of human genes. 
Meta-analyses including more than 2000 patients, specifically looking at radiological response, 
progression free survival and overall survival, demonstrated in some subgroups a trend in favour of 
better outcome for the wild type alleles (especially in asian population), while the opposite has been 
observed in other patient populations (e.g. Caucasian patients), thus confirming the inconsistency of 
these findings.
However, the effect of ERCC1 polymorphisms on toxicity has been under-reported, and when 
analysed a more consistent effect could be observed, in the sense that the presence of mutated 
variants was associated to an increased risk of common chemotherapy-related side effects, possibly 
because of the reduced DNA repair efficiency and increased toxic effect of platinum adducts in 
normal tissues and cells, such as hematopoietic cells.
No meta-analyses has been so far conducted on this issue, and comprehensive safety data including 
also minor toxicities (i.e. grade 2 toxicity), which still can significantly impair full treatment 
delivery, are clearly lacking in the literature.
Such a lacking aspect, prompted us to systematically assess in our Unit the effect of ERCC1 (and 
other key genes) polymorphisms in a homogenous group of patients treated with oxaliplatin, 
specifically looking at the association with changes in haematological variables.
Even though in only 16 patients, we could confirm a predictive value of ERCC1 rs3212986 for the 
risk of haemoglobin decline and anemia during adjuvant FOLFOX. In our ‘real life’ research, 
rs3212986 heterozygous patients treated with standard adjuvant chemotherapy seem to be at 
increased risk of treatment delay and early discontinuation because of substantial haemoglobin 
reduction (three patients with a rs3212986 MUT allele out of 16 had to discontinue/delay the 
treatment because of chemotherapy-induced anemia). It is well known that maintaining dose 
intensity in adjuvant treatment is crucial for reducing the risk of disease relapse and hence overall 
survival.[53,54] Moreover, chemotherapy toxicity is a key determinant of quality of life in cancer 
patients [55].
If this finding is confirmed with further patient enrolment, it will be likely that a practice changing 
amendment is introduced in our treatment policy, and rs3212986 heterozygous patients will start 
chemotherapy with upfront reduced doses of oxaliplatin.
In fact, in this case of ERCC1 genotyping, a ‘sliding doors’ trial would be a trial when the very 
same patient is treated either with an unknown genotype at standard chemotherapy doses or with an 
upfront dose reduction according to a known pre-chemotherapy ERCC1 genotype showing the risk 
of anemia, to see if a pharmacogenetic-oriented dose adjustment will reduce the risk of adjuvant 
chemotherapy delay or early discontinuation and eventually influence survival. 
In conclusion, even though we acknowledge that these results have to be confirmed after an 
adequate sample size enhancement, we think that confirmatory monocentric studies are always 
desirable, in the absence of an ideal ‘sliding doors’ trial.
Figure 4 schematic representation of differences between a hypothetical ‘sliding doors’ trial, a large randomized 
clinical trial (RCT) and monocentric single arm study, with associated correction factors to be introduced in the 
decision making process.
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 A review of the literature on the effect of ERCC1 polymorphisms on oxaliplatin efficacy 
and safety is proposed
 Available evidence does not support ERCC1 genotyping to predict survival or radiologic 
response in oxaliplatin-treated patients
 ERCC1 minor alleles of rs3212986 and rs11615 polymorphisms have been consistently 
associated with increased oxaliplatin toxicity and we confirmed this finding in our clinical 
centre
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ABSTRACT
Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair 
mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent 
oxaliplatin. Germline ERCC1 polymorphisms may alter the protein expression and published data 
on their predictive and prognostic value have so far been contradictory. In the present article we 
review available evidence on the clinical role and utility of ERCC1 polymorphisms and, in the 
absence of a ‘perfect’ trial, what we call the ‘sliding doors’ trial, we present the data of ERCC1 
genotyping in our local patient population finding a useful predictive value for oxaliplatin-induced 
risk of anemia.
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